Scientific Presentations

Tolerability and Preliminary Efficacy of BXQ-350 for Solid Tumors and Gliomas: First-in-human, first-in-class phase 1 trial

Conflict of Interest Statement: Dr. Rixe holds a minor (<0.01%) equity interest in Bexion Pharmaceuticals, Inc.

On Tuesday, June 22, 2021, Dr. Ray Takigiku, Founder and CEO of Bexion, participated in AngelMD’s Pitch Club, “Innovations in Oncology”.

Immunostimulating Properties of BXQ-350

BXQ-350: Stimulating the Immune System by Modulating Phosphatidylserine Expression and Sphingolipid Signaling

BXQ-350: Stimulating the Immune System by Modulating Phosphatidylserine Expression and Sphingolipid Signaling